United Therapeutics Corporation Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
United Therapeutics Corporation (UTHR) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $1.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-25
- United Therapeutics Corporation unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $1.80M, a 100.00% increase from fiscal 2024.
- United Therapeutics Corporation unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $900.00K, a 52.63% decline from fiscal 2023.
- United Therapeutics Corporation unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $1.90M.
- United Therapeutics Corporation unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.80M 10-K · filed 2026-02-25 | |
| 2024-12-31 | $900.00K 10-K · filed 2026-02-25 | |
| 2023-12-31 | $1.90M 10-K · filed 2026-02-25 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-26 | |
| 2021-12-31 | $0.00 10-K · filed 2024-02-21 | |
| 2016-12-31 | $0.00 10-K · filed 2017-02-22 | |
| 2015-12-31 | $900.00K 10-K · filed 2017-02-22 | $945.00K 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |